207 related articles for article (PubMed ID: 9916992)
21. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer.
Spring K; Ahangari F; Scott SP; Waring P; Purdie DM; Chen PC; Hourigan K; Ramsay J; McKinnon PJ; Swift M; Lavin MF
Nat Genet; 2002 Sep; 32(1):185-90. PubMed ID: 12195425
[TBL] [Abstract][Full Text] [Related]
22. Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL.
Luo L; Lu FM; Hart S; Foroni L; Rabbani H; Hammarström L; Yuille MR; Catovsky D; Webster AD; Vorechovský I
Cancer Res; 1998 Jun; 58(11):2293-7. PubMed ID: 9622061
[TBL] [Abstract][Full Text] [Related]
23. Interaction between ATM protein and c-Abl in response to DNA damage.
Shafman T; Khanna KK; Kedar P; Spring K; Kozlov S; Yen T; Hobson K; Gatei M; Zhang N; Watters D; Egerton M; Shiloh Y; Kharbanda S; Kufe D; Lavin MF
Nature; 1997 May; 387(6632):520-3. PubMed ID: 9168117
[TBL] [Abstract][Full Text] [Related]
24. A single ataxia telangiectasia gene with a product similar to PI-3 kinase.
Savitsky K; Bar-Shira A; Gilad S; Rotman G; Ziv Y; Vanagaite L; Tagle DA; Smith S; Uziel T; Sfez S; Ashkenazi M; Pecker I; Frydman M; Harnik R; Patanjali SR; Simmons A; Clines GA; Sartiel A; Gatti RA; Chessa L; Sanal O; Lavin MF; Jaspers NG; Taylor AM; Arlett CF; Miki T; Weissman SM; Lovett M; Collins FS; Shiloh Y
Science; 1995 Jun; 268(5218):1749-53. PubMed ID: 7792600
[TBL] [Abstract][Full Text] [Related]
25. ATM and related protein kinases: safeguarding genome integrity.
Shiloh Y
Nat Rev Cancer; 2003 Mar; 3(3):155-68. PubMed ID: 12612651
[TBL] [Abstract][Full Text] [Related]
26. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer.
Lavin MF
Nat Rev Mol Cell Biol; 2008 Oct; 9(10):759-69. PubMed ID: 18813293
[TBL] [Abstract][Full Text] [Related]
27. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination.
Bredemeyer AL; Sharma GG; Huang CY; Helmink BA; Walker LM; Khor KC; Nuskey B; Sullivan KE; Pandita TK; Bassing CH; Sleckman BP
Nature; 2006 Jul; 442(7101):466-70. PubMed ID: 16799570
[TBL] [Abstract][Full Text] [Related]
28. Regulation of ATM in DNA double strand break repair accounts for the radiosensitivity in human cells exposed to high linear energy transfer ionizing radiation.
Xue L; Yu D; Furusawa Y; Okayasu R; Tong J; Cao J; Fan S
Mutat Res; 2009 Nov; 670(1-2):15-23. PubMed ID: 19583974
[TBL] [Abstract][Full Text] [Related]
29. DNA damage-induced signalling in ataxia-telangiectasia and related syndromes.
Lavin MF; Kozlov S
Radiother Oncol; 2007 Jun; 83(3):231-7. PubMed ID: 17512070
[TBL] [Abstract][Full Text] [Related]
30. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.
Golding SE; Rosenberg E; Neill S; Dent P; Povirk LF; Valerie K
Cancer Res; 2007 Feb; 67(3):1046-53. PubMed ID: 17283137
[TBL] [Abstract][Full Text] [Related]
31. Functional consequences of ATM sequence variants for chromosomal radiosensitivity.
Gutiérrez-Enríquez S; Fernet M; Dörk T; Bremer M; Lauge A; Stoppa-Lyonnet D; Moullan N; Angèle S; Hall J
Genes Chromosomes Cancer; 2004 Jun; 40(2):109-19. PubMed ID: 15101044
[TBL] [Abstract][Full Text] [Related]
32. [Ataxia-telangiectasia and cancer: an open question].
Rodriguez C; Theillet C
Bull Cancer; 1997 Jul; 84(7):763-6. PubMed ID: 9339205
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration.
Yang DQ; Halaby MJ; Li Y; Hibma JC; Burn P
Drug Discov Today; 2011 Apr; 16(7-8):332-8. PubMed ID: 21315178
[TBL] [Abstract][Full Text] [Related]
34. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia.
Lavin MF; Gueven N; Bottle S; Gatti RA
Br Med Bull; 2007; 81-82():129-47. PubMed ID: 17586848
[TBL] [Abstract][Full Text] [Related]
35. Recombinant ATM protein complements the cellular A-T phenotype.
Ziv Y; Bar-Shira A; Pecker I; Russell P; Jorgensen TJ; Tsarfati I; Shiloh Y
Oncogene; 1997 Jul; 15(2):159-67. PubMed ID: 9244351
[TBL] [Abstract][Full Text] [Related]
36. The many substrates and functions of ATM.
Kastan MB; Lim DS
Nat Rev Mol Cell Biol; 2000 Dec; 1(3):179-86. PubMed ID: 11252893
[TBL] [Abstract][Full Text] [Related]
37. In search of drug treatment for genetic defects in the DNA damage response: the example of ataxia-telangiectasia.
Shiloh Y; Andegeko Y; Tsarfaty I
Semin Cancer Biol; 2004 Aug; 14(4):295-305. PubMed ID: 15219622
[TBL] [Abstract][Full Text] [Related]
38. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart.
Shiloh Y
Annu Rev Genet; 1997; 31():635-62. PubMed ID: 9442910
[TBL] [Abstract][Full Text] [Related]
39. ATM: the product of the gene mutated in ataxia-telangiectasia.
Lavin MF
Int J Biochem Cell Biol; 1999 Jul; 31(7):735-40. PubMed ID: 10467728
[TBL] [Abstract][Full Text] [Related]
40. Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms.
Watters D; Khanna KK; Beamish H; Birrell G; Spring K; Kedar P; Gatei M; Stenzel D; Hobson K; Kozlov S; Zhang N; Farrell A; Ramsay J; Gatti R; Lavin M
Oncogene; 1997 Apr; 14(16):1911-21. PubMed ID: 9150358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
